Tolerance of ocular iontophoresis in healthy volunteers

被引:63
作者
Parkinson, TM
Ferguson, E
Febbraro, S
Bakhtyari, A
King, M
Mundasad, M
机构
[1] Iomed Inc, Res & Dev, Salt Lake City, UT 84120 USA
[2] Simbec Res Ltd, Merthyr Tydfil CF48 4DR, M Glam, Wales
[3] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England
关键词
DRUG-DELIVERY;
D O I
10.1089/108076803321637672
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
To evaluate ocular tolerance, healthy volunteers were iontophoresed transclerally using novel OcuPhor(TM) hydrogel drug delivery applicators filled with balanced salt solution. In this three-period crossover study in 24 male and female subjects, 16 subjects received 0 mA and two of the following DC currents: 0.1, 0.5., 1.0, 2.0, 3.0, or 4.0 mA for 20 min; 6 subjects received 3 mA for 20 min and 1.5 mA for 40 min (both equivalent to 60 mAmin total charge). Safety and tolerance were determined by subjective VAS and objective ophthalmic assessments. Subjects were evaluated before and up to 22 hr after dosing. The applicators were well-tolerated and no clinically significant changes in symptomology or in ophthalmic assessments were seen following exposure to 0-3.0 mA for 20 min or 1.5 mA for 40 min. At 4.0 mA 2 of 4 subjects reported a burning sensation under the applicator during dosing which resolved by 22 hr post-dose; superficial changes in fluorescein staining were observed at 1 hr, but not at 22 hr. The OcuPhor(TM) system has promise for noninvasive drug delivery to the eye.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 12 条
[1]   IONTOPHORETIC DELIVERY OF DRUGS - FUNDAMENTALS, DEVELOPMENTS AND BIOMEDICAL APPLICATIONS [J].
BANGA, AK ;
CHIEN, YW .
JOURNAL OF CONTROLLED RELEASE, 1988, 7 (01) :1-24
[2]  
CHIESA R, 1999, EMERGING THERAPEUTIC, V3, P527
[3]  
Fischer GA., 2002, DRUG DELIVERY TECHNO, V2, P50
[4]  
Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
[5]   Current status and future prospects of transdermal drug delivery [J].
Guy, RH .
PHARMACEUTICAL RESEARCH, 1996, 13 (12) :1765-1769
[6]  
HILL JM, 1993, DRUGS PHARM SCI, V58, P331
[7]  
Parkinson TM, 2000, INVEST OPHTH VIS SCI, V41, pS772
[8]   THE ROLE OF IONTOPHORESIS IN OCULAR DRUG-DELIVERY [J].
SARRAF, D ;
LEE, DA .
JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (01) :69-81
[9]  
SZLEK MA, 2002, ARVO ANN M FT LAUD F
[10]  
VOLLMER DL, 2002, ARVO ANN M FT LAUD F